| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cell Growth & Differentiation |
Departments of Biochemistry and Molecular Genetics [I. D. L., H. G., J. M. R.] and Pathology [R. P. B.], Division of Hematology/Oncology, Department of Medicine, and the Comprehensive Cancer Center [P. M-B., J. M. R.], School of Medicine [B. C. B.], University of Alabama at Birmingham, Birmingham, Alabama 35294-3300
The protein synthetic machinery is activated by diverse genetic alterations during tumor progression in vivo and represents an attractive target for cancer therapy. We show that rapamycin inhibits the induction of transformed foci in vitro by GLI, a transcription factor that functions in the sonic hedgehog-patched pathway in tumors. In control cells, which were nontransformed epithelioid RK3E cells and derivative c-MYC- or RAS-transformed sister cell lines, rapamycin inhibits mTOR and mTOR-dependent activities but increases global protein synthesis, perhaps by activating a feedback mechanism. In GLI-transformed cells, rapamycin inhibits global protein synthesis and turnover and prevents cellular proliferation. In contrast to its effects on protein synthesis, rapamycin affects bromodeoxyuridine incorporation and cell cycle occupancy of GLI cells and control cells to a similar extent. Rare, variant GLI cells isolated by selection in rapamycin are also drug-resistant for protein metabolism and for cell cycle progression through G1. Our results indicate that sensitivity to rapamycin can be induced by a specific oncogene and that inhibition of global protein metabolism is linked to the rapamycin-sensitive phenotype.
This article has been cited by other articles:
![]() |
B. Bhatia, P. A. Northcott, D. Hambardzumyan, B. Govindarajan, D. J. Brat, J. L. Arbiser, E. C. Holland, M. D. Taylor, and A. M. Kenney Tuberous Sclerosis Complex Suppression in Cerebellar Development and Medulloblastoma: Separate Regulation of Mammalian Target of Rapamycin Activity and p27Kip1 Localization Cancer Res., September 15, 2009; 69(18): 7224 - 7234. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. R. Parathath, L. A. Mainwaring, A. Fernandez-L, D. O. Campbell, and A. M. Kenney Insulin receptor substrate 1 is an effector of sonic hedgehog mitogenic signaling in cerebellar neural precursors Development, October 1, 2008; 135(19): 3291 - 3300. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Kopelovich, J. R. Fay, C. C. Sigman, and J. A. Crowell The Mammalian Target of Rapamycin Pathway as a Potential Target for Cancer Chemoprevention Cancer Epidemiol. Biomarkers Prev., July 1, 2007; 16(7): 1330 - 1340. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Maeda, W. Fu, A. Ortin, M. de las Heras, and H. Fan Roles of the Ras-MEK-Mitogen-Activated Protein Kinase and Phosphatidylinositol 3-Kinase-Akt-mTOR Pathways in Jaagsiekte Sheep Retrovirus-Induced Transformation of Rodent Fibroblast and Epithelial Cell Lines J. Virol., April 1, 2005; 79(7): 4440 - 4450. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Tang, M. Kmet, L. Corral, S. Vartanian, A. Tobler, and J. Papkoff Testisin, a Glycosyl-Phosphatidylinositol-Linked Serine Protease, Promotes Malignant Transformation In vitro and In vivo Cancer Res., February 1, 2005; 65(3): 868 - 878. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. S. Goehring, D. M. Rivers, and G. F. Sprague Jr. Urmylation: A Ubiquitin-like Pathway that Functions during Invasive Growth and Budding in Yeast Mol. Biol. Cell, November 1, 2003; 14(11): 4329 - 4341. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. D. Louro, E. C. Bailey, X. Li, L. S. South, P. R. McKie-Bell, B. K. Yoder, C. C. Huang, M. R. Johnson, A. E. Hill, R. L. Johnson, et al. Comparative Gene Expression Profile Analysis of GLI and c-MYC in an Epithelial Model of Malignant Transformation Cancer Res., October 15, 2002; 62(20): 5867 - 5873. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Y. Leung, F. T. Kolligs, R. Wu, Y. Zhai, R. Kuick, S. Hanash, K. R. Cho, and E. R. Fearon Activation of AXIN2 Expression by beta -Catenin-T Cell Factor. A FEEDBACK REPRESSOR PATHWAY REGULATING Wnt SIGNALING J. Biol. Chem., June 7, 2002; 277(24): 21657 - 21665. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. W. Foster, A. R. Frost, P. McKie-Bell, C.-Y. Lin, J. A. Engler, W. E. Grizzle, and J. M. Ruppert Increase of GKLF Messenger RNA and Protein Expression during Progression of Breast Cancer Cancer Res., November 1, 2000; 60(22): 6488 - 6495. [Abstract] [Full Text] |
||||
![]() |
B. K. Law, P. Norgaard, and H. L. Moses Farnesyltransferase Inhibitor Induces Rapid Growth Arrest and Blocks p70s6k Activation by Multiple Stimuli J. Biol. Chem., April 6, 2000; 275(15): 10796 - 10801. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. E. Cardenas, N. S. Cutler, M. C. Lorenz, C. J. Di Como, and J. Heitman The TOR signaling cascade regulates gene expression in response to nutrients Genes & Dev., December 15, 1999; 13(24): 3271 - 3279. [Abstract] [Full Text] |
||||
![]() |
M. Aoki, E. Blazek, and P. K. Vogt A role of the kinase mTOR in cellular transformation induced by the oncoproteins P3k and Akt PNAS, January 2, 2001; 98(1): 136 - 141. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cell Growth & Differentiation |